Add-on iguratimod as a therapeutic strategy to achieve remission in patients with rheumatoid arthritis inadequately responding to biological DMARDs: A retrospective study.

about

Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study.Serum matrix metalloproteinase 3 levels are associated with an effect of iguratimod as add-on therapy to biological DMARDs in patients with rheumatoid arthritis

P2860

Q52653996-34A7059D-83C6-4296-A3F1-88254B5146B3 Q58715277-5D00E7D8-88E0-4A1B-A4F3-7CF9217FAC08

P2860

Add-on iguratimod as a therapeutic strategy to achieve remission in patients with rheumatoid arthritis inadequately responding to biological DMARDs: A retrospective study.

Item

http://www.wikidata.org/entity/Q48744497

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Add-on iguratimod as a therape ...... DMARDs: A retrospective study.

@en

Add-on iguratimod as a therape ...... DMARDs: A retrospective study.

@nl

type

Item

label

Add-on iguratimod as a therape ...... DMARDs: A retrospective study.

@en

Add-on iguratimod as a therape ...... DMARDs: A retrospective study.

@nl

prefLabel

Add-on iguratimod as a therape ...... DMARDs: A retrospective study.

@en

Add-on iguratimod as a therape ...... DMARDs: A retrospective study.

@nl

P1476

Add-on iguratimod as a therape ...... DMARDs: A retrospective study.

@en

P2093

Ayaka Yoshikawa

http://www.w3.org/2001/XMLSchema#string

Nao Tokai

http://www.w3.org/2001/XMLSchema#string

Shigeki Makino

http://www.w3.org/2001/XMLSchema#string

Shuzo Yoshida

http://www.w3.org/2001/XMLSchema#string

Takuya Kotani

http://www.w3.org/2001/XMLSchema#string

Tohru Takeuchi

http://www.w3.org/2001/XMLSchema#string

Yohei Fujiki

http://www.w3.org/2001/XMLSchema#string

Yoko Matsumura

http://www.w3.org/2001/XMLSchema#string

Yuko Kimura

http://www.w3.org/2001/XMLSchema#string

P2860

Prevalence of ultrasound-detected residual synovitis and risk of relapse and structural progression in rheumatoid arthritis patients in clinical remission: a systematic review and meta-analysis

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis

Remission in patients with active rheumatoid arthritis by tocilizumab treatment in routine clinical practice: results from 3 years of prospectively registered data.

Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study).

Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study.

An anti-rheumatic agent T-614 inhibits NF-kappaB activation in LPS- and TNF-alpha-stimulated THP-1 cells without interfering with IkappaBalpha degradation.

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values

Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study

P304

1-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14397595.2017.1336865

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28644744

http://www.w3.org/2001/XMLSchema#string

Add-on iguratimod as a therapeutic strategy to achieve remission in patients with rheumatoid arthritis inadequately responding to biological DMARDs: A retrospective study.

about

P2860

P2860

Add-on iguratimod as a therapeutic strategy to achieve remission in patients with rheumatoid arthritis inadequately responding to biological DMARDs: A retrospective study.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P577

P698